Esperite

Esperite EBITDA

Delisted

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Esperite (ESP.AS) as of Nov 16, 2026 is -4.50 M EUR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -2.52 M EUR — a change of 78.65% (lower).

EBITDA

-4.50 MEUR

YoY

78.65%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Esperite is 2017 -4.50 M EUR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Esperite was 2016 -2.52 M EUR. It decreases by 78.65% lower compared to the previous year.

The Esperite EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2014
-3.45 M EUR
Jan 1, 2015
-4.86 M EUR
Jan 1, 2016
-2.52 M EUR
Jan 1, 2017
-4.50 M EUR
The Esperite EBITDA history
YEAREBITDAYoY
-4.50 MEUR+78.65%
-2.52 MEUR-48.09%
-4.86 MEUR+40.85%
-3.45 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Esperite Stock analysis

What does Esperite do? Esperite NV is a company based in the Netherlands that specializes in the development, production, and marketing of stem cell and cell therapies. It focuses on creating groundbreaking therapies for the treatment of serious diseases and aims to market them worldwide. Its business model includes three main segments: Life Science, Consumer Healthcare, and Branding. The Life Science segment focuses on developing stem cell and cell therapies for the treatment of diseases such as autism, cancer, and degenerative disorders. The Consumer Healthcare segment offers products related to pregnancy and fertility assistance. The Branding segment involves the development and marketing of high-quality cosmetic products. Esperite's flagship product is CryoSave, a solution for the long-term preservation of stem cells from umbilical cord blood. Esperite is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Esperite stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Esperite is -4.50 M EUR in 2017.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Esperite changed from -2.52 M EUR to -4.50 M EUR, representing a 78.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Esperite since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Esperite historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Esperite

All Key Metrics — Esperite